Moomoo AIのまとめ
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in Adial Pharmaceuticals, Inc. This stake amounts to 166,972 shares in the company's common stock. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Consequently, both Armistice Capital and Steven Boyd may be deemed to beneficially own the securities of Adial Pharmaceuticals held by the Master Fund. The Master Fund, however, disclaims beneficial ownership of these securities due to its Investment Management Agreement with Armistice Capital, which limits its ability to vote or dispose...Show More
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in Adial Pharmaceuticals, Inc. This stake amounts to 166,972 shares in the company's common stock. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Consequently, both Armistice Capital and Steven Boyd may be deemed to beneficially own the securities of Adial Pharmaceuticals held by the Master Fund. The Master Fund, however, disclaims beneficial ownership of these securities due to its Investment Management Agreement with Armistice Capital, which limits its ability to vote or dispose of the securities. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain investment advisers and parent holding companies. The report emphasizes that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
2023年12月31日、Armistice Capital, LLCとその経営メンバーのスティーザン・ボイドは、米国証券取引委員会にスケジュール13Gを提出し、Adial Pharmaceuticals, Inc.の9.99%の所有権を開示しました。この割合は同社の普通株式166,972株に相当します。報告書によれば、Armistice CapitalはArmistice Capital Master Fund Ltd.の投資マネージャーとして、Master Fundが保有する証券に対して投票権と投資権を行使します。そのため、Armistice Capitalとスティーザン・ボイドの両者がMa...すべて展開
2023年12月31日、Armistice Capital, LLCとその経営メンバーのスティーザン・ボイドは、米国証券取引委員会にスケジュール13Gを提出し、Adial Pharmaceuticals, Inc.の9.99%の所有権を開示しました。この割合は同社の普通株式166,972株に相当します。報告書によれば、Armistice CapitalはArmistice Capital Master Fund Ltd.の投資マネージャーとして、Master Fundが保有する証券に対して投票権と投資権を行使します。そのため、Armistice Capitalとスティーザン・ボイドの両者がMaster Fundが保有するAdial Pharmaceuticalsの証券を有益に所有しているとみなされる可能性があります。ただしMaster Fundは、Armistice Capitalとの投資管理契約により、その証券について投票権や処分権を行使する能力が制限されているため、これらの証券について有益な所有権を放棄します。この報告書は、投資顧問や親会社に適用される証券取引法のルール13d-1（b）に従って提出されました。報告書は、これらの株式が業務上の通常の取引目的で取得され、Adial Pharmaceuticalsの支配権を変更または影響を与えることを目的としていないことを強調しています。
役に立った
役に立たない
